PGNY vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 23, 2026

PGNY

64.4
AI Score
VS
PGNY Wins

CLOV

34.3
AI Score

Investment Advisor Scores

PGNY

64score
Recommendation
BUY

CLOV

34score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PGNY CLOV Winner
Revenue 679.01M 1.49B CLOV
Net Income 52.28M 55.34M CLOV
Net Margin 7.7% 3.7% PGNY
Operating Income 75.38M 55.34M PGNY
ROE 11.5% 14.7% CLOV
ROA 7.3% 7.7% CLOV
Total Assets 715.84M 720.33M CLOV
Current Ratio 2.14 1.50 PGNY
Free Cash Flow 83.81M 131.55M CLOV

Relative Price Performance (Last 90 Days)

PGNY 1M: -16.4% · 3M: +3.9% CLOV 1M: -8.8% · 3M: +15.3%

Current Technical Phase

PGNY

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 34

RSI (14): 33.5 · Price: $25.65

CLOV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 43

RSI (14): 42.8 · Price: $4.15

Fundamentals Snapshot

Metric PGNY CLOV
Market Cap
Forward P/E 11.3 27.7
Trailing P/E 27.9
Revenue (TTM)
Revenue Growth 0.1% 0.6%
Gross Margin 0.2% 0.2%
Operating Margin 0.1% 0.0%
EPS 0.92 -0.05
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PGNY is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.